Pharmaceutical
Biotechnology
Biopharmaceutical

Alexion Pharmaceuticals

$130.21
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$4.00 (-2.98%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell ALXN and other stocks, options, ETFs, and crypto commission-free!

About

Alexion Pharmaceuticals, Inc. Common Stock, also called Alexion Pharmaceuticals, is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Read More Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Employees
2,656
Headquarters
Boston, Massachusetts
Founded
1992
Market Cap
30.00B
Price-Earnings Ratio
393.83
Dividend Yield
0.00
Average Volume
1.62M
High Today
$134.77
Low Today
$130.12
Open Price
$133.86
Volume
537.08K
52 Week High
$140.77
52 Week Low
$92.56

Collections

Pharmaceutical
Biotechnology
Biopharmaceutical
Health
Therapy
Technology
US
North America

News

Seeking AlphaMar 20

Achillion Pharmaceuticals: The Promise Of Alternative Pathway Inhibition

One of ACH-4471 weaknesses is its dosing schedule and potency and as a response, Achillion is developing more potent next-gen factor D inhibitors.

10
Seeking AlphaMar 20

Alexion teams up with Affibody AB to develop candidate for IgG-mediated disorders

Alexion Pharmaceuticals (NASDAQ:ALXN) will collaborate with Swedish biotech Affibody AB to develop candidate ABY-039 for rare immunoglobulin G (IgG)-mediated autoimmune disorders.

7
Seeking AlphaMar 20

Alexion teams up with Zealand Pharma in peptide therapies

Alexion Pharmaceuticals (NASDAQ:ALXN) will collaborate with Zealand Pharma A/S (NASDAQ:ZEAL) to discover and develop novel subcutaneously administered peptide therapies for complement-mediated disorders.

3

Earnings

$1.25
$1.55
$1.84
$2.14
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 25, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.